Transdermal rivastigmine: Management of cutaneous adverse events and review of the literature

CNS Drugs

Volumn 25, Issue 7, 2011, Pages 575-583

  Greenspoon, Jill ^a,d,e   Herrmann, Nathan ^b,c   Adam, David N ^b,d  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e NONE   (Canada)

Author keywords

Allergic contact dermatitis; Alzheimers disease; Corticosteroids; Irritant contact dermatitis; Rivastigmine; Transdermal

Indexed keywords

BETAMETHASONE VALERATE; CORTICOSTEROID; DODECYL SULFATE; FLUTICASONE PROPIONATE; HYDROCORTISONE; RIVASTIGMINE;

ALLERGIC REACTION; ALZHEIMER DISEASE; CHOLINERGIC NERVE CELL; CONFUSION; CORTICOSTEROID THERAPY; DECREASED APPETITE; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; IRRITANT DERMATITIS; NAUSEA; NEUROTRANSMISSION; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN ALLERGY; SKIN MANIFESTATION; SWEATING; VOMITING;

ADMINISTRATION, CUTANEOUS; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, CONTACT; HUMANS; MEDICATION ADHERENCE; PHENYLCARBAMATES; TRANSDERMAL PATCH;

EID: 79959556986     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11592230-000000000-00000     Document Type: Review

References (34)

1. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimers disease [letter]. Lancet 1976; 2: 1403 (Pubitemid 8004505)
2. Weinstock M. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimers disease. CNS Drugs 1999; 12: 307-23 (Pubitemid 29503416)
3. Eisai Co. FDA accepts Aricept Patch (donepezil transdermal system) NDA for review [media release]. 2010 Sep 17 [online]. Available from URL: http://www.eisai.com/news/ enews201049pdf [Accessed 2011 May 11]
4. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimers disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65 (Pubitemid 28323228)
5. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimers disease. Int J Geriatr Psychopharmacol 1998; 1: S26-34 (Pubitemid 28563272)
6. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002; (127): 45-63 (Pubitemid 34778530)
7. Winblad B, Grossberg B, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69: 14-22
8. Lefèvre G, Sedek G, Jhee S, et al Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimers disease patients. Clin Pharmacol Ther 2008 83 106-14
9. Zhai H, Maibach HI, editors. Dermatotoxicology. 6th ed. New York (NY): CRC Press LLC, 2004
10. Grossberg GT, Sadowsky S, Olin JT. Rivastigmine transdermal systemfor the treatment ofmild tomoderateAlzheimers disease. Int J Clin Pract 2010; 64: 534-6
11. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimers disease. Int J Geriatr Psychiatry 2007; 22: 485-91 (Pubitemid 46831693)
12. Bernabei R, Mart?nez Lage P. Clinical benefits associated with a transdermal patch for dementia. Eur Neurol Rev 2008; 3: 10-3
13. Exelon- Patch (rivastigmine transdermal system): full prescribing information [online]. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2010. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/ exelon patch.pdf [Accessed 2011 May 11]
14. Ale I, Lachapelle JM, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther 2009; 26: 920-35
15. Widman TJ, Oostman H, Storrs FJ. Allergic contact dermatitis from medical adhesive bandages in patients who report having a reaction to medical bandages. Dermatitis 2008; 19: 32-7 (Pubitemid 351428409)
16. Sadowsky C, Dengiz A, Olin J, et al. Switching from donezepil tablets to rivastigmine transdermal patch in Alzheimers disease. Am J Alz Dis Other Demen 2009; 24: 267-75
17. Beltrani VS, Beltrani VP. Contact dermatitis. Ann Allergy Asthma Immunol 1997; 78: 160-73
18. Saary J, Qureshi R, Palda V, et al. A systematic review of contact dermatitis treatment and prevention. J Am Acad Dermatol 2005; 53: 845
19. Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician 2010; 82: 249-55
20. Zeller S, Warshaw E. Allergic contact dermatitis. Minn Med 2004; 87: 38-42
21. Loden M. Barrier recovery and influence of irritant stimuli in skin treated with a moisturizing cream. Contact Dermatitis 1997; 36: 256-60 (Pubitemid 27246448)
22. Loden M, Andersson AC. Effect of topically applied lipids on surfactant-irritated skin. Br J Dermatol 1996; 134: 215-20 (Pubitemid 26054441)
23. Queille-Roussel C, Duteil L, Padilla JM, et al. Efficacy of topical corticosteroids in nickel-induced contact allergy. Clin Exp Dermatol 2002; 27: 47-50
24. Levin C, Zhai H, Bashir S, et al. Efficacy of corticosteroids in acute experimental irritant contact dermatitis. Skin Res Technol 2001; 7: 214-8 (Pubitemid 33064716)
25. Zhai H, Brachman F, Pelosi A, et al. A bioengineering study on the efficacy of a skin protectant lotion in preventing SLS-induced dermatitis. Skin Res Technol 2000; 6: 77-80 (Pubitemid 30248947)
26. Perrenoud D, Gallezot D, van Melle G. The efficacy of a protective cream in a real-world apprentice hairdresser environment. Contact Dermatitis 2001; 45: 134-8 (Pubitemid 32800359)
27. Amkraut AA, Jordan WP, Taskovich I. Effect of coadministration of corticosteroids on the development of contact sensitization. J Am Acad Dermatol 1996; 35: 27-31 (Pubitemid 26231318)
28. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003; 17: 493-503 (Pubitemid 37138884)
29. Berardesca E, BarbareschiM, Veraldi S, et al. Evaluation of efficacy of a skin lipid mixture in patients with irritant contact dermatitis, allergic contact dermatitis or atopic dermatitis: a multicenter study. Contact Dermatitis 2001; 45: 280-5 (Pubitemid 33032967)
30. Berman B, France DS, Martinelli GP, et al. Modulation of expression of epidermal Langerhans cell properties following in situ exposure to glucocorticosteroids. J Invest Dermatol 1983; 80: 168-71 (Pubitemid 13152662)
31. Toews GB, Bergstreser PR, Streilein JW. Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB. J Immunol 1980; 124: 445-53 (Pubitemid 10182298)
32. Lefevre G, Sedek G, Huang HL, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007; 47: 471-8 (Pubitemid 46465956)
33. Arnold LE, Lindsay RL, Lopez FA, et al. Treating attentiondeficit/ hyperactivity disorder with a stimulant transdermal patch: the clinical art. Pediatrics 2007; 120: 1100-6 (Pubitemid 350085550)
34. Health Canada. Drugs and health products [online]. Available from URL: http://hc-sc.gc.ca/dhp-mps/medeff/advisoriesavis/ prof/-2010/exelon-hpc-cps-eng. php [Accessed 2011 May 10]